AI discharge summaries meet noninferiority in five London hospitals; ward mobility program fails to improve outcomes; FDA flags luer valve risk

Listen to this post
read by AI voices · all episodesDischarge summaries drafted by a large language model met a noninferiority margin for clinician signoff against clinician-written ones at five London hospitals, a JAMA Network Open study found Nov. 17.
A Swiss cluster trial of a ward mobility program showed no gain in life-space mobility, and the Food and Drug Administration (FDA) issued early alerts on B. Braun luer access valves and Heraeus vascular guidewires.
- AI Nov 17, 2026A retrospective JAMA Network Open study published Nov. 17 compared 645 discharge summaries generated by GPT-4o mini from health record data with 649 written by clinicians, reviewed by 12 practicing physicians against the full admission record. The primary end point, signoff with no or minor edits, favored the model by 22.2 percentage points, and the lower bound exceeded the prespecified noninferiority margin of -5 points. The authors said the model's summaries met the current standard of care and described the use as one requiring close clinician oversight.Source: JAMA Network Open
- Research Nov 16, 2026The INTOMOB cluster randomized trial, published in JAMA Network Open Nov. 16, tested booklets and videos for patients, staff training and ward posters on general internal medicine wards of three Swiss hospitals in 383 older patients with a median age of 75. Short-term life-space mobility did not differ significantly between groups (adjusted difference 0.67 points; 95% CI -4.35 to 5.68), and the authors said the program did not improve other clinical outcomes either.Source: JAMA Network Open
- Policy Nov 16, 2026The Department of Health and Human Services (HHS) Office for Civil Rights issued a final rule Nov. 16 modifying the HIPAA Privacy Rule. It cuts the time to respond to patient requests for record copies from 30 calendar days to 15, Healthcare Dive reported, and establishes a right to receive electronic records through a personal health app, amends access fees and reduces identity verification burdens, according to HHS. It also permits disclosures to social services agencies and community-based organizations. The rule takes effect 60 days after publication, with compliance due 180 days after that, Healio reported.
- Public health Nov 17, 2026The U.S. has lost the measles elimination status it earned 26 years ago, officials announced Nov. 17, after the Pan American Health Organization (PAHO) found the virus had circulated uninterrupted for more than a year, Healio reported; news reports of the decision appeared Nov. 14. Countries that lose the status must submit a plan to PAHO for getting measles back under control. In a joint statement, Centers for Disease Control and Prevention (CDC) Director Dr. Erica Schwartz said, "The measles elimination designation is not what protects Americans. Vaccination does."
- FDA Nov 19, 2026The Food and Drug Administration (FDA) posted an early alert Nov. 19 on B. Braun's Caresite Micro luer access device, whose internal piston can remain depressed after a male luer is disconnected. Possible consequences include blood loss, interruption or delay of therapy and air embolism, which may cause serious injury and, rarely, death. B. Braun told users to inspect devices after disconnection and replace any that leak or show backflow, and reported no serious injuries or deaths as of Nov. 3.Source: FDA
- AI Nov 17, 2026A Journal of General Internal Medicine meta-analysis published Nov. 17 pooled 28 studies with 4,647 participants on point-of-care ultrasound for reduced left ventricular systolic function. Five studies of AI-assisted ultrasound yielded a diagnostic odds ratio of 47.35 (95% CI 16.87 to 132.93), nine of visual qualitative assessment 40.53 (95% CI 15.07 to 109.00) and seven of E-point septal separation 21.77 (95% CI 10.25 to 46.28), with no significant differences among methods, the authors said. The comparison rests on accuracy studies, not patient outcomes.
- FDA Nov 20, 2026The Food and Drug Administration (FDA) posted an early alert Nov. 20 on Heraeus Medical Components' removal of Navilyst, Spectrum and Arrow Marked vascular guidewires used for peripheral vessel access by the Seldinger technique. The hydrophilic coating can swell inconsistently and clump, raising the potential for flaking, displacement or detachment; reported consequences range from asymptomatic deposits to vascular occlusion, ischemia and infarction. Heraeus told facilities to stop using the products and quarantine affected lots, and reported no serious injuries or deaths as of Nov. 5.Source: FDA
The weekly innovation roundup for hospital medicine, published every Sunday for the week before; every item links to its sources. Latest hospital medicine news · All specialties